PMID- 35080187
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220328
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 18
IP  - 6
DP  - 2022 Feb
TI  - A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer 
      patients with malignant pleural effusion.
PG  - 669-677
LID - 10.2217/fon-2021-1035 [doi]
AB  - Aim: To investigate the efficacy, safety and optimal dosage of bevacizumab in 
      non-squamous, non-small-cell lung cancer (NSCLC) patients with malignant pleural 
      effusion (MPE). Methods: 20 patients were enrolled and received intrapleural 
      injection of bevacizumab (group A: 2.5 mg/kg d1, d8; group B: 5 mg/kg d1, d8; 
      group C: 7.5 mg/kg d1, d8). Results: The objective response rate (ORR) of MPE was 
      50%. The median progression-free survival (PFS) of MPE was 7.0 months (95% CI 
      4.9-9.2). The ORR and PFS of MPE from group B were better than those of group A 
      and group C. The most common adverse events (AEs) were hypertension (15%) and 
      anemia (15%). Conclusion: Bevacizumab has certain efficacy in non-squamous NSCLC 
      patients with MPE. Clinical Trial Registration: NCT02942043 (ClinicalTrials.gov).
FAU - Di, Wu
AU  - Di W
AUID- ORCID: 0000-0002-6993-8350
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Yue, Cong
AU  - Yue C
AD  - Department of Ultrasound, Key Laboratory of Carcinogenesis & Translational 
      Research (Ministry of Education/Beijing), Peking University Cancer Hospital & 
      Institute, Beijing, 100142, China.
FAU - Ziran, Zhang
AU  - Ziran Z
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Jie, Zhang
AU  - Jie Z
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Jun, Nie
AU  - Jun N
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Ling, Dai
AU  - Ling D
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Weiheng, Hu
AU  - Weiheng H
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Xiaoling, Chen
AU  - Xiaoling C
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Xiangjuan, Ma
AU  - Xiangjuan M
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Guangming, Tian
AU  - Guangming T
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Jindi, Han
AU  - Jindi H
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Sen, Han
AU  - Sen H
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Yang, Wang
AU  - Yang W
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Jieran, Long
AU  - Jieran L
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
FAU - Jian, Fang
AU  - Jian F
AD  - Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital & Institute, Beijing, 100142 China.
LA  - eng
SI  - ClinicalTrials.gov/NCT02942043
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220126
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Aged
MH  - Angiogenesis Inhibitors/*administration & dosage/adverse effects
MH  - Antineoplastic Agents, Immunological/*administration & dosage/adverse effects
MH  - Bevacizumab/*administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*complications/drug therapy
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*complications/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pleural Effusion, Malignant/*drug therapy/etiology
MH  - Progression-Free Survival
MH  - Prospective Studies
OTO - NOTNLM
OT  - bevacizumab
OT  - malignant pleural effusion
OT  - non-small-cell lung cancer
OT  - phase II
EDAT- 2022/01/27 06:00
MHDA- 2022/03/29 06:00
CRDT- 2022/01/26 08:37
PHST- 2022/01/27 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2022/01/26 08:37 [entrez]
AID - 10.2217/fon-2021-1035 [doi]
PST - ppublish
SO  - Future Oncol. 2022 Feb;18(6):669-677. doi: 10.2217/fon-2021-1035. Epub 2022 Jan 
      26.